CSIMarket
 


United Therapeutics Corporation  (UTHR)
Other Ticker:  
 
 

UTHR's EPS from Cont. Operations Growth by Quarter and Year

United Therapeutics's EPS from Cont. Operations results by quarter and year




UTHR EPS from Cont. Operations (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 4.61 2.88 2.48 2.23
III Quarter September 5.71 5.26 3.62 3.86
II Quarter June 5.53 2.56 3.85 2.43
I Quarter March 5.20 5.31 0.63 3.14
FY   21.05 16.01 10.58 11.66



UTHR EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
United Therapeutics Corporation achieved in the fourth quarter 2023, above Company average EPS from Cont. Operations rise of 60.05% year on year, to $ 4.61 .

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 9 other companies have achieved higher EPS from Cont. Operations growth. While United Therapeutics Corporation' s EPS from Cont. Operations jump of 60.05% ranks overall at the positon no. 629 in the fourth quarter 2023.




UTHR EPS from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 60.05 % 16.13 % 11.21 % 85.83 %
III Quarter September 8.56 % 45.3 % -6.22 % 27.81 %
II Quarter June 116.02 % -33.51 % 58.44 % -48.08 %
I Quarter March -2.07 % 742.86 % -79.94 % -
FY   31.48 % 51.32 % -9.26 % -

Financial Statements
United Therapeutics's fourth quarter 2023 EPS from Cont. Operations $ 4.61 UTHR's Income Statement
United Therapeutics's fourth quarter 2022 EPS from Cont. Operations $ 2.88 Quarterly UTHR's Income Statement
New: More UTHR's historic EPS from Cont. Operations Growth >>


UTHR EPS from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -19.28 % -45.25 % -31.49 % -42.23 %
III Quarter September 3.25 % 105.47 % -5.97 % 58.85 %
II Quarter June 6.35 % -51.79 % 511.11 % -22.61 %
I Quarter March 80.56 % 114.11 % -71.75 % 161.67 %
FY (Year on Year)   31.48 % 51.32 % -9.26 % -




EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #46
Overall #629

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
507.84 % 19.01 % -130.2 %
(June 30. 2016)   (Mar 31 2019)
EPS from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #46
Overall #629
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
507.84 % 19.01 % -130.2 %
(June 30. 2016)   (Mar 31 2019)

EPS from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

United Therapeutics's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
10755.26 % 343.8 % -99.25 %
(Dec 31 2012)  


UTHR's IV. Quarter Q/Q EPS from Cont. Operations Comment
In the IV. Quarter 2023 United Therapeutics Corporation realized fall in EPS from Cont. Operations sequentially by -19.28% to $ 4.61 , from $ 5.71 released in the previous reporting period.

When you evaluate current downturn in the IV. Quarter 2023, you must assume, that commonly IV. Quarter EPS from Cont. Operations emerge weaker in contrast to the third quarter

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While United Therapeutics's EPS from Cont. Operations growth quarter on quarter, overall rank is 877.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #68
Overall #877
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #68
Overall #877
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
10755.26 % 343.8 % -99.25 %
(Dec 31 2012)  


UTHR's IV. Quarter Q/Q EPS from Cont. Operations Comment
In the IV. Quarter 2023 United Therapeutics Corporation realized fall in EPS from Cont. Operations from the third quarter by -19.28% to $ 4.61 , from $ 5.71 released in the previous reporting period.

As we analyse current downturn in the quarter, we should assume, that frequently IV. Quarter performance appear to be softer relative to the third quarter

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While United Therapeutics's EPS from Cont. Operations growth quarter on quarter, overall rank is 877.


United Therapeutics's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ 21.05 $ 19.32 $ 18.87 $ 15.90 $ 16.01
Y / Y EPS from Cont. Operations Growth (TTM) 31.49 % 23.78 % 35.09 % 4.2 % 51.35 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 217 # 277 # 169 # 292 # 990
Seqeuential EPS from Cont. Operations Change (TTM) 8.96 % 2.38 % 18.68 % -0.69 % 2.57 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 629 # 628 # 1166 # 397 # 807




Cumulative EPS from Cont. Operations growth Comment
United Therapeutics saw improvement in EPS from Cont. Operations growth trend, posting cumulative 12 months EPS from Cont. Operations growth of 31.49% year on year, to $ 21 if the fiscal year would have ended in Dec 31 2023.
United Therapeutics's trailing twelve months EPS from Cont. Operations growth was higher than company's average 19.01% and higher than 23.78% growth in Sep 30 2023.
But sequential growth rate was slower at 8.96 % from $19.32 reported in twelve months ending a quarter before.
It appears to be stagnation developing, more evident if you pay attention to the As we typical sequential historic rise what is better at19.01% Alexander Thomas wrote.
The growth was even stronger from the previous reporting period exhibited at 8.96 % increase from $19.32 in twelve months ending a quarter before.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While Total ranking has impoved so far to 217, from total ranking in previous quarter at 277.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
507.84 %
19.01 %
-130.2 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 16
Overall # 217

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
507.84 %
19.01 %
-130.2 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 46
S&P 500 # 629
Cumulative EPS from Cont. Operations growth Comment
United Therapeutics saw improvement in EPS from Cont. Operations growth trend, posting cumulative 12 months EPS from Cont. Operations growth of 31.49% year on year, to $ 21 if the fiscal year would have ended in Dec 31 2023.
United Therapeutics's trailing twelve months EPS from Cont. Operations growth was higher than company's average 19.01% and higher than 23.78% growth in Sep 30 2023.
But from the previous reporting period rise was beneth at 8.96 % from $19.32 achieved in the period from Sep 30 2023 to Dec 31 2022.
There is drop-off in progress, more obvious if you pay attention to the As we typical sequential historic increase that is higher at 19.01%.
The progress was even more impressive sequentially exhibited at 8.96 % jump from $19.32 in twelve months ending a quarter before.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While Total ranking has impoved so far to 217, from total ranking in previous quarter at 277.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
507.84 %
19.01 %
-130.2 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 16
Overall # 217

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
507.84 %
19.01 %
-130.2 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 46
S&P 500 # 629




Other EPS from Cont. Operations Growth
Major Pharmaceutical Preparations Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
UTHR's EPS from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for UTHR's Competitors
EPS from Cont. Operations Growth for United Therapeutics's Suppliers
EPS from Cont. Operations Growth for UTHR's Customers

You may also want to know
UTHR's Annual Growth Rates UTHR's Profitability Ratios UTHR's Asset Turnover Ratio UTHR's Dividend Growth
UTHR's Roe UTHR's Valuation Ratios UTHR's Financial Strength Ratios UTHR's Dividend Payout Ratio
UTHR's Roa UTHR's Inventory Turnover Ratio UTHR's Growth Rates UTHR's Dividend Comparisons



Companies with similar EPS from Cont. Operations fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Dec 31 2023
Stryker Corp102.31%$ 102.306 
Alpha Pro Tech Ltd 102.01%$ 102.011 
Corcept Therapeutics Inc98.20%$ 98.198 
Quest Diagnostics Inc96.11%$ 96.115 
Intuitive Surgical Inc 86.05%$ 86.050 
Astrazeneca Plc81.13%$ 81.132 
Dr Reddy s Laboratories Limited76.47%$ 76.471 
3m Company72.40%$ 72.405 
Electromed Inc 66.67%$ 66.667 
Select Medical Holdings Corp65.65%$ 65.648 
Neurocrine Biosciences Inc 63.08%$ 63.082 
United Therapeutics Corporation60.16%$ 60.158 
Cytek Biosciences Inc 57.66%$ 57.659 
Abbott Laboratories55.26%$ 55.256 
Halozyme Therapeutics Inc 55.17%$ 55.172 
Tactile Systems Technology Inc 52.10%$ 52.101 
Lemaitre Vascular Inc 48.69%$ 48.693 
Msa Safety Incorporated46.19%$ 46.189 
Integer Holdings Corporation44.60%$ 44.597 
Chemed Corporation43.12%$ 43.119 
Healthcare Services Group Inc 40.85%$ 40.848 
Viemed Healthcare Inc 40.75%$ 40.751 
Ufp Technologies Inc 36.08%$ 36.083 
Hologic Inc35.53%$ 35.526 
Catalyst Pharmaceuticals Inc 34.07%$ 34.071 
West Pharmaceutical Services Inc 33.63%$ 33.631 
National Research Corporation33.56%$ 33.559 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com